Key result
Tricuspid valvuloplasty linked to ~94% lower early mortality vs. replacement in Ebstein's anomaly.
Why the study?
The incidence of Ebstein's anomaly is extremely low, and except for the Mayo Clinic, no cardiac center has reported outcomes of a sufficient number of patients treated with tricuspid valvuloplasty or replacement.
Population
245 Ebstein's anomaly patients treated from July 2006 to April 2016
Comparison
Tricuspid valvuloplasty vs tricuspid valve replacement
Design
Cohort study
Follow-up
Mean 43.6 ± 32.6 months
Authors
Loading...
Valvuloplasty may reduce early mortality versus replacement in Ebstein's anomaly; extends prior cohorts but leaves open need for prospective trials.
Cohort (n=224)
No
Absolute Event Rate: 0.5% vs 8.7%
p-value: p=0.028
Li et al. (2018) conducted a cohort in Ebstein's anomaly (n=224). Tricuspid valvuloplasty vs. Tricuspid valve replacement was evaluated on Early mortality rate (p=0.028). Tricuspid valvuloplasty resulted in a significantly lower early mortality rate compared to tricuspid valve replacement (0.5% vs. 8.7%, P = 0.028) in patients with Ebstein's anomaly.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: